A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

被引：0

作者：

Muro, Kei

Kim, Tae Won

Park, Young Suk

Uetake, Hiroyuki

Nishina, Tomohiro

Nozawa, Hiroaki

Matsumoto, Hiroshi

Yamazaki, Kentaro

Han, Sae-Won

Lee, Keun-Wook

Deng, Yanhong

Buyse, Marc E.

Satoh, Taroh

Ryoo, Baek-Yeol

Shen, Lin

Iwasa, Satoru

Morita, Satoshi

Sakamoto, Junichi

Xu, Rui-hua

机构：

[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[4] Tokyo Med & Dent Univ, Dept Surg Specialties, Tokyo, Japan

[5] Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[6] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan

[7] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan

[8] Shizuoka Canc Ctr, Shizuoka, Japan

[9] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp,Canc Res Inst, Seoul 151, South Korea

[10] Seoul Natl Univ, Coll Med, Bundang Hosp, Seoul, South Korea

[11] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China

[12] Int Inst Drug Dev, Cambridge, MA USA

[13] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan

[14] Beijing Canc Hosp, Beijing, Peoples R China

[15] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan

[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[17] Tokai Cent Hosp, Kakamigahara, Japan

[18] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.tps780

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS780

引用

下载

页数：1

共 50 条

[1] A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT)
Nakamura, Masato
Kim, Tae Won
Xu, Rui-hua
Park, Young Suk
Hong, Yong Sang
Zhang, Tao
Kato, Takeshi
Cho, Sang Hee
Wang, Wei
Matsuoka, Hiroshi
Han, Sae-Won
Deng, Yanhong
Makiyama, Akitaka
Lee, Keun-Wook
Ba, Yi
Ota, Mitsuyoshi
Iwasa, Satoru
Morita, Satoshi
Yamada, Yasuhide
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[2] Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI plus bevacizumab versus FOLFIRI plus bevacizumab (AXEPT)
Kim, T. W.
Park, Y. S.
Muro, K.
Xu, R.
Han, S.
Yamazaki, K.
Wang, W.
Ahn, J. B.
Uetake, H.
Deng, Y.
Cho, S.
Matsumoto, H.
Ba, Y.
Lee, K-W.
Nishina, T.
Zhang, T.
Iwasa, S.
Morita, S.
Sakamoto, J.
ANNALS OF ONCOLOGY, 2017, 28 : 186 - 186
[3] Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Kotaka, Masahito
Xu, Ruihua
Muro, Kei
Park, Young Suk
Morita, Satoshi
Iwasa, Satoru
Uetake, Hiroyuki
Nishina, Tomohiro
Nozawa, Hiroaki
Matsumoto, Hiroshi
Yamazaki, Kentaro
Han, Sae-Won
Wang, Wei
Ahn, Joong Bae
Deng, Yanhong
Cho, Sang-Hee
Ba, Yi
Lee, Keun-Wook
Zhang, Tao
Satoh, Taroh
Buyse, Marc E.
Ryoo, Baek-Yeol
Shen, Lin
Sakamoto, Junichi
Kim, Tae Won
CHINESE JOURNAL OF CANCER, 2016, 35 : 102
[4] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Ahmet, Bilici
Uygun, Kazim
Kaya, Serap
Ustaalioglu, Bala Basak Oven
Yildiz, Ramazan
Temiz, Suleyman
Seker, Mesut
Aksu, Gorkem
Cabuk, Devrim
Gumus, Mahmut
ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
[5] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
Ocvirk, J.
Rebersek, M.
Boc, M.
EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
[6] A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese PatientsWithMetastatic Colorectal Cancer (BIX Study)
Hamamoto, Yasuo
Yamaguchi, Tatsuro
Nishina, Tomohiro
Yamazaki, Kentaro
Ura, Takashi
Nakajima, Takako
Goto, Ayumu
Shimada, Ken
Nakayama, Norisuke
Sakamoto, Junichi
Yamada, Yasuhide
ONCOLOGIST, 2014, 19 (11): : 1131 - 1132
[7] Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).
Pectasides, D. G.
Xanthakis, I.
Makatsoris, T.
Samantas, E.
Varthalitis, I.
Papaxoinis, G.
Papakotoulas, P.
Boumakis, E.
Papandreou, C.
Fountzilas, G.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8] Xeliri Plus Bevacizumab Compared with Folfiri Plus Bevacizumab as First-Line Setting in Patients with Metastatic Colorectal Cancer: Experiences at Two-Institutions
Uygun, Kazim
Bilici, Ahmet
Kaya, Serap
Ustaalioglu, Bala Basak Oven
Yildiz, Ramazan
Temiz, Suleyman
Seker, Mesut
Aksu, Gorkem
Cabuk, Devrim
Gumus, Mahmut
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (04) : 2283 - 2288
[9] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
Yosuke Horita
Yasuhide Yamada
Ken Kato
Yoshinori Hirashima
Kouhei Akiyoshi
Kengo Nagashima
Takako Nakajima
Tetsuya Hamaguchi
Yasuhiro Shimada
International Journal of Clinical Oncology, 2012, 17 : 604 - 609
[10] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
Horita, Yosuke
Yamada, Yasuhide
Kato, Ken
Hirashima, Yoshinori
Akiyoshi, Kouhei
Nagashima, Kengo
Nakajima, Takako
Hamaguchi, Tetsuya
Shimada, Yasuhiro
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (06) : 604 - 609

← 1 2 3 4 5 →